Asciminib as Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission

The purpose of this study is to determine if taking asciminib may induce continued deep molecular responses in more patients with newly diagnosed CML to make them eligible for treatment discontinuation. We will also investigate whether, for those who do not reach the deepest molecular responses, adding nilotinib might be able to produce a continued MR4.5 response, allowing them the option of treatment discontinuation.